Neurology Intelligence Agent -- Learning Guide: Foundations¶
Version: 1.0.0 Date: 2026-03-22 Author: Adam Jones
Purpose¶
This guide provides the neuroscience and clinical neurology foundations needed to understand, operate, and extend the Neurology Intelligence Agent. It covers brain anatomy, major neurological disease categories, clinical assessment scales, and diagnostic modalities. No prior neurology knowledge is assumed.
1. Neuroanatomy Primer¶
1.1 Major Brain Regions¶
| Region | Location | Key Functions | Clinical Relevance |
|---|---|---|---|
| Frontal lobe | Anterior | Executive function, motor control, speech production (Broca's area), personality | FTD, frontal lobe epilepsy, GBM |
| Temporal lobe | Lateral | Memory (hippocampus), language comprehension (Wernicke's area), auditory processing | TLE, Alzheimer's, herpes encephalitis |
| Parietal lobe | Superior-posterior | Sensory integration, spatial awareness, calculation | Stroke (neglect), PCA variant AD |
| Occipital lobe | Posterior | Visual processing | Posterior cortical atrophy, visual field deficits |
| Cerebellum | Inferior-posterior | Coordination, balance, motor learning | MSA-C, spinocerebellar ataxia, medulloblastoma |
| Brainstem | Central-inferior | Consciousness, cranial nerves, respiratory drive, autonomic function | Basilar stroke, MSA, PSP |
| Basal ganglia | Deep gray matter | Movement initiation, motor planning | Parkinson's disease, Huntington's, dystonia |
| Hippocampus | Medial temporal | Memory consolidation, spatial navigation | Alzheimer's (earliest affected), TLE |
| Thalamus | Diencephalon | Sensory relay, consciousness | Stroke, fatal familial insomnia |
| Spinal cord | Vertebral canal | Motor pathways, sensory pathways, reflexes | MS, ALS, myelopathy, SCI |
1.2 The Neurovascular Anatomy¶
Understanding vascular territories is essential for stroke localization:
- Anterior cerebral artery (ACA): Medial frontal and parietal lobes. Stroke causes leg > arm weakness.
- Middle cerebral artery (MCA): Lateral hemisphere, including motor/sensory cortex, Broca's and Wernicke's areas. Most common stroke territory. Causes face + arm > leg weakness, aphasia (if dominant hemisphere).
- Posterior cerebral artery (PCA): Occipital lobe, medial temporal. Stroke causes visual field loss (homonymous hemianopia).
- Basilar artery: Brainstem, cerebellum. Occlusion is life-threatening -- "locked-in syndrome."
- Circle of Willis: Anastomotic ring connecting anterior and posterior circulations. Aneurysms here cause subarachnoid hemorrhage.
1.3 The Blood-Brain Barrier¶
The blood-brain barrier (BBB) is a selectively permeable membrane separating circulating blood from the brain. It limits drug delivery to the CNS, making neurological drug design challenging. The BBB is disrupted in: - Brain tumors (allows contrast enhancement on MRI) - MS (active lesions show gadolinium enhancement) - Acute stroke (after reperfusion) - Infections (meningitis, encephalitis)
2. Stroke: Cerebrovascular Disease¶
2.1 Stroke Types¶
| Type | Mechanism | % of Strokes | Acute Treatment |
|---|---|---|---|
| Ischemic | Artery blocked by clot | ~87% | IV tPA (0-4.5h), thrombectomy (0-24h) |
| Hemorrhagic (ICH) | Blood vessel rupture | ~10% | BP control, reversal of anticoagulation |
| Subarachnoid (SAH) | Aneurysm rupture | ~3% | Aneurysm securing (clip or coil), nimodipine |
| TIA | Transient occlusion | -- | Secondary prevention (antiplatelet, statin) |
2.2 TOAST Classification of Ischemic Stroke¶
| Subtype | Mechanism | Typical Workup |
|---|---|---|
| Large artery atherosclerosis | Carotid/intracranial stenosis | CTA, carotid duplex |
| Cardioembolic | Atrial fibrillation, valve disease | ECG, echo, cardiac monitoring |
| Small vessel occlusion (lacunar) | Lipohyalinosis of perforating arteries | MRI (small deep infarcts) |
| Other determined etiology | Dissection, vasculitis, hypercoagulable | Specific testing |
| Cryptogenic | Unknown after full workup | Extended cardiac monitoring |
2.3 Key Clinical Scales for Stroke¶
NIHSS (NIH Stroke Scale): 15-item scale (0-42) quantifying stroke severity. Used to guide tPA and thrombectomy decisions. Score >= 6 triggers CTA for large vessel occlusion evaluation.
ASPECTS (Alberta Stroke Program Early CT Score): 10-region CT scoring system for MCA territory ischemia. Score starts at 10; subtract 1 per affected region. Score >= 6 is favorable for intervention.
mRS (Modified Rankin Scale): Global disability outcome measure (0-6). Score 0-2 = good functional outcome. Used as primary endpoint in stroke trials.
2.4 Time Windows¶
- IV tPA: 0-4.5 hours from symptom onset (NINDS, ECASS III)
- Mechanical thrombectomy (standard): 0-6 hours (MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, REVASCAT)
- Extended window thrombectomy: 6-16 hours (DEFUSE-3), 6-24 hours (DAWN) -- requires imaging selection
3. Dementia and Neurodegenerative Disease¶
3.1 The Dementia Spectrum¶
Dementia is not a single disease but a syndrome of progressive cognitive decline sufficient to interfere with daily function. Major subtypes:
| Subtype | % of Dementia | Key Features | Pathology |
|---|---|---|---|
| Alzheimer's disease | ~60-70% | Memory loss first, then language, visuospatial | Amyloid plaques + tau tangles |
| Vascular dementia | ~15-20% | Stepwise decline, often after strokes | White matter disease, infarcts |
| Lewy body dementia | ~5-10% | Visual hallucinations, fluctuating cognition, parkinsonism | Alpha-synuclein Lewy bodies |
| Frontotemporal dementia | ~5-10% | Behavioral changes OR language decline | Tau or TDP-43 |
| Mixed | Common | Features of multiple subtypes | Combined pathology |
3.2 The ATN Framework¶
The NIA-AA ATN framework (2018) stages Alzheimer's disease biologically:
- A (Amyloid): Measured by amyloid PET or CSF Abeta42. Marks the earliest pathological change.
- T (Tau): Measured by tau PET or CSF phospho-tau. Correlates with neuronal injury.
- N (Neurodegeneration): Measured by FDG-PET, MRI volumetrics, or CSF total tau/NfL. Correlates with clinical severity.
Each is binary (+ or -), yielding 8 possible profiles. A+T+N+ = full biological Alzheimer's disease.
3.3 Cognitive Screening¶
MoCA (Montreal Cognitive Assessment): 30-point screening tool covering visuospatial, naming, attention, language, abstraction, delayed recall, and orientation. Score < 26 suggests cognitive impairment. Education adjustment: +1 point if <= 12 years education.
MMSE (Mini-Mental State Examination): 30-point exam. Less sensitive than MoCA for MCI. Commonly used for tracking progression.
3.4 Anti-Amyloid Therapies (2024-2026)¶
- Lecanemab (Leqembi): FDA-approved 2023. Binds soluble amyloid protofibrils. CLARITY AD trial showed 27% slowing of cognitive decline. Requires amyloid PET or CSF confirmation.
- Donanemab (Kisunla): FDA-approved 2024. Targets deposited amyloid plaques. TRAILBLAZER-ALZ 2 showed 35% slowing in early AD.
- Risk: ARIA (amyloid-related imaging abnormalities) -- brain edema and microhemorrhages. Requires MRI monitoring.
4. Seizures and Epilepsy¶
4.1 Seizure Classification (ILAE 2017)¶
The International League Against Epilepsy classifies seizures by onset:
Seizure Types
|
+-- Focal Onset (starts in one hemisphere)
| +-- Aware (consciousness preserved)
| +-- Impaired Awareness (consciousness impaired)
| +-- Focal to Bilateral Tonic-Clonic
|
+-- Generalized Onset (starts in both hemispheres)
| +-- Motor: Tonic-Clonic, Tonic, Clonic, Myoclonic, Atonic
| +-- Non-Motor: Absence (typical, atypical)
|
+-- Unknown Onset
4.2 Key Epilepsy Syndromes¶
| Syndrome | Onset Age | Key Features | First-Line ASM | Gene |
|---|---|---|---|---|
| Childhood absence | 4-10 years | Staring spells, 3Hz spike-wave on EEG | Ethosuximide, valproate | GABRG2 |
| Juvenile myoclonic (JME) | 12-18 years | Morning myoclonic jerks, GTC | Valproate, levetiracetam | EFHC1 |
| Temporal lobe (TLE) | Any | Deja vu, epigastric rising, automatisms | Carbamazepine, lamotrigine | Usually acquired |
| Dravet | < 1 year | Prolonged febrile seizures, refractory | Stiripentol, CBD, fenfluramine | SCN1A |
| Lennox-Gastaut | 1-7 years | Drop attacks, slow spike-wave on EEG | Valproate, lamotrigine, CBD | Multiple |
| West (infantile spasms) | 3-12 months | Epileptic spasms, hypsarrhythmia on EEG | ACTH, vigabatrin (if TSC) | Multiple |
4.3 Drug-Resistant Epilepsy¶
ILAE definition: Failure of two appropriately chosen and tolerated anti-seizure medications to achieve sustained seizure freedom. Affects ~30% of epilepsy patients.
Surgical options: - Anterior temporal lobectomy: Gold standard for TLE with MTS. 60-80% seizure freedom. - Laser ablation (LITT): Minimally invasive, MRI-guided. - VNS (vagus nerve stimulation): Palliative; ~50% reduction in seizures. - RNS (responsive neurostimulation): Closed-loop brain stimulation. For eloquent cortex.
4.4 Medication Safety¶
Critical concept: Some ASMs can worsen seizures in certain syndromes. Sodium channel blockers (carbamazepine, phenytoin, oxcarbazepine) are contraindicated in Dravet syndrome (SCN1A mutation) and may worsen absence and myoclonic seizures in JME.
5. Multiple Sclerosis¶
5.1 What is MS?¶
Multiple sclerosis is a chronic autoimmune disease where the immune system attacks myelin (the insulating sheath around nerve fibers) in the brain and spinal cord. This causes inflammation, demyelination, and axonal damage.
5.2 MS Phenotypes¶
| Phenotype | Description | % of Patients |
|---|---|---|
| CIS | First clinical episode of demyelination | ~85% present this way |
| RRMS | Relapses followed by recovery; stable between attacks | ~85% at diagnosis |
| SPMS | Progressive worsening after initial RRMS phase | ~50% of RRMS after 15-20 years |
| PPMS | Progressive from onset, no relapses | ~15% at diagnosis |
5.3 Diagnosis: McDonald Criteria (2017)¶
MS diagnosis requires demonstration of dissemination in: - Space: Lesions in >= 2 of 4 CNS areas (periventricular, cortical/juxtacortical, infratentorial, spinal cord) - Time: Simultaneous Gd-enhancing and non-enhancing lesions, OR new lesion on follow-up MRI, OR OCB in CSF
5.4 Disease-Modifying Therapies (DMTs)¶
| Tier | Agents | Efficacy | Key Risks |
|---|---|---|---|
| Platform | Interferon beta, glatiramer | Low-moderate | Injection-site reactions, flu-like |
| Moderate | Dimethyl fumarate, fingolimod, ozanimod | Moderate | Lymphopenia, cardiac (fingolimod) |
| High | Ocrelizumab, natalizumab, ofatumumab, alemtuzumab | High | Infection risk, PML (natalizumab) |
5.5 NEDA-3 (No Evidence of Disease Activity)¶
Treatment goal: achieve NEDA-3 defined as: 1. No clinical relapses 2. No new or enlarging T2 MRI lesions 3. No EDSS progression (confirmed at 3-6 months)
5.6 EDSS (Expanded Disability Status Scale)¶
The EDSS (0-10, 0.5 steps) grades disability based on 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral) plus ambulation. Score 6.0 = requires walking aid. Score 7.0 = wheelchair bound.
6. Movement Disorders and Parkinson's Disease¶
6.1 Parkinson's Disease¶
Parkinson's disease is the second most common neurodegenerative disorder. Caused by loss of dopaminergic neurons in the substantia nigra.
Cardinal motor features (must have bradykinesia plus one other): - Bradykinesia (slowness of movement) - Resting tremor (4-6 Hz, "pill-rolling") - Rigidity (cogwheel or lead-pipe) - Postural instability (later feature)
Non-motor features (often precede motor symptoms): - REM sleep behavior disorder (dream enactment) - Hyposmia (reduced smell) - Constipation - Depression, anxiety - Cognitive impairment (late)
6.2 Parkinson's Staging: Hoehn and Yahr¶
| Stage | Description |
|---|---|
| 1 | Unilateral involvement only |
| 1.5 | Unilateral + axial involvement |
| 2 | Bilateral, no balance impairment |
| 2.5 | Mild bilateral with recovery on pull test |
| 3 | Bilateral with postural instability, functionally independent |
| 4 | Severe disability, can walk/stand unassisted |
| 5 | Wheelchair or bed-bound |
6.3 Treatment Approach¶
- Levodopa/carbidopa (Sinemet): Gold standard. Most effective symptomatic therapy. Can cause dyskinesias with long-term use.
- Dopamine agonists (pramipexole, ropinirole): Alternative to levodopa. Risk of impulse control disorders.
- MAO-B inhibitors (rasagiline, safinamide): Mild benefit, fewer side effects.
- DBS (deep brain stimulation): For motor fluctuations/dyskinesias despite optimal medication. Targets: subthalamic nucleus (STN) or globus pallidus interna (GPi).
6.4 MDS-UPDRS Part III¶
The motor examination portion of the MDS-UPDRS has 33 sub-scores (each 0-4), maximum 132. Used to track disease progression and medication response. A score >= 59 raises consideration for DBS candidacy.
7. Headache Disorders¶
7.1 ICHD-3 Classification¶
The International Classification of Headache Disorders (3rd edition) divides headaches into: - Primary: Migraine, tension-type, trigeminal autonomic cephalalgias, other - Secondary: Due to underlying cause (tumor, SAH, infection, medication) - Painful neuropathies and facial pains: Trigeminal neuralgia, etc.
7.2 Migraine¶
| Feature | Migraine Without Aura | Migraine With Aura |
|---|---|---|
| Duration | 4-72 hours | 4-72 hours |
| Quality | Pulsating, unilateral | + Visual/sensory/language aura (5-60 min) |
| Associated | Nausea, photophobia, phonophobia | Aura precedes headache |
| Chronic | >= 15 days/month for >= 3 months | -- |
7.3 Red Flags (SNOOP Criteria)¶
| Red Flag | Concern |
|---|---|
| Systemic symptoms (fever, weight loss) | Infection, malignancy |
| Neurological signs | Mass lesion, stroke |
| Onset sudden (thunderclap) | SAH, cerebral venous thrombosis |
| Older age (new headache > 50) | Giant cell arteritis, tumor |
| Positional, progressive, precipitated by Valsalva | Elevated ICP, Chiari malformation |
7.4 Treatment Evolution¶
Traditional preventives (topiramate, propranolol, amitriptyline, valproate) are being supplemented by CGRP-targeted therapies: - CGRP monoclonal antibodies: Erenumab (Aimovig), galcanezumab (Emgality), fremanezumab (Ajovy) - Gepants (CGRP receptor antagonists): Atogepant (Qulipta) for prevention, rimegepant (Nurtec) and ubrogepant (Ubrelvy) for acute treatment - Ditans: Lasmiditan (Reyvow) -- 5-HT1F agonist, no vasoconstriction
8. Neuromuscular Disease¶
8.1 Anatomical Localization¶
| Level | Examples | EMG/NCS Pattern |
|---|---|---|
| Motor neuron | ALS, SMA | Active denervation, large MUAPs |
| Nerve root | Radiculopathy | Dermatomal distribution |
| Peripheral nerve | Neuropathy (diabetic, CIDP) | Axonal or demyelinating |
| Neuromuscular junction | Myasthenia gravis, LEMS | Decrement (MG) or increment (LEMS) on RNS |
| Muscle | Myopathy, myositis | Small MUAPs, early recruitment |
8.2 ALS (Amyotrophic Lateral Sclerosis)¶
- Progressive motor neuron disease affecting both upper and lower motor neurons
- Diagnosis: El Escorial criteria (definite, probable, possible)
- ALSFRS-R scale (0-48): Tracks functional decline across 12 items
- Treatments: Riluzole (extends survival ~3 months), edaravone, tofersen (SOD1-ALS)
- Median survival: 3-5 years from symptom onset
8.3 Myasthenia Gravis¶
- Autoimmune NMJ disorder. Antibodies: AChR (85%), MuSK (5-10%), LRP4 (rare)
- Presents with fatigable weakness: ptosis, diplopia, bulbar weakness, respiratory failure
- Diagnosis: AChR antibodies + decremental response on repetitive nerve stimulation
- Treatment: Pyridostigmine, immunosuppression, thymectomy, crisis management (IVIg, PLEX)
- New: Efgartigimod (Vyvgart) -- FcRn inhibitor
9. Clinical Scales in Practice¶
How the Agent Uses Scales¶
Each validated clinical scale in the agent serves a specific decision-making role:
- Screening: MoCA detects cognitive impairment; HIT-6 quantifies headache disability
- Severity grading: NIHSS grades stroke severity; UPDRS Part III grades Parkinson's motor impairment
- Treatment eligibility: NIHSS >= 6 triggers LVO evaluation; EDSS progression triggers DMT escalation
- Prognosis: mRS predicts stroke outcome; ALSFRS-R decline rate predicts ALS survival
- Imaging interpretation: ASPECTS grades CT findings; Hoehn-Yahr stages PD
- Intervention threshold: GCS <= 8 triggers intubation; UPDRS >= 59 triggers DBS evaluation
10. Diagnostic Modalities¶
10.1 Neuroimaging¶
| Modality | Best For | Examples |
|---|---|---|
| CT head | Acute hemorrhage, fracture | Stroke alert, trauma |
| CT angiography | Vascular occlusion | LVO detection, aneurysm |
| MRI brain | Structural detail, MS lesions, tumors | All chronic conditions |
| DWI (diffusion) | Acute ischemia | Stroke within minutes-hours |
| FLAIR | White matter disease | MS lesions, chronic ischemia |
| MR spectroscopy | Metabolite profiles | Tumor vs. abscess vs. demyelination |
| FDG-PET | Metabolism | Dementia differential (AD vs. FTD) |
| Amyloid PET | Amyloid plaques | Alzheimer's confirmation |
| DAT scan | Dopamine transporter | PD vs. essential tremor |
10.2 Electrophysiology¶
| Test | Measures | Clinical Use |
|---|---|---|
| EEG | Brain electrical activity | Seizure diagnosis, encephalopathy |
| EMG | Muscle electrical activity | Motor neuron disease, myopathy |
| NCS | Nerve conduction velocity/amplitude | Neuropathy classification |
| Evoked potentials | Visual, somatosensory, auditory pathways | MS, optic neuritis, spinal cord |
| Repetitive nerve stimulation | NMJ function | Myasthenia gravis, LEMS |
10.3 CSF Analysis¶
| Test | Normal | Abnormal In |
|---|---|---|
| Opening pressure | 6-20 cm H2O | IIH (elevated), CSF leak (low) |
| WBC count | 0-5 cells/uL | Meningitis, encephalitis |
| Protein | 15-45 mg/dL | GBS, meningitis, tumor |
| Glucose | 50-80 mg/dL | Bacterial meningitis (low) |
| Oligoclonal bands | Absent | MS (present in >90%) |
| Abeta42 | Normal | Low in AD |
| Phospho-tau | Normal | Elevated in AD |
Glossary¶
| Term | Definition |
|---|---|
| ASM/AED | Anti-seizure medication / anti-epileptic drug |
| BBB | Blood-brain barrier |
| CSF | Cerebrospinal fluid |
| DBS | Deep brain stimulation |
| DMT | Disease-modifying therapy (for MS) |
| EEG | Electroencephalogram |
| EMG | Electromyography |
| FLAIR | Fluid-attenuated inversion recovery (MRI sequence) |
| LVO | Large vessel occlusion |
| MoCA | Montreal Cognitive Assessment |
| NIHSS | NIH Stroke Scale |
| NMJ | Neuromuscular junction |
| RAG | Retrieval-Augmented Generation |
| tPA | Tissue plasminogen activator |
Neurology Intelligence Agent -- Learning Guide: Foundations v1.0.0 HCLS AI Factory / GTC Europe 2026